Background of the Guideline

TheUS Food and Drug Administration (FDA) has issued the final guidance on 'Postapproval Pregnancy Safety Studies' to proactively secure safety information on drug exposure during pregnancy. Previously, due to concerns about risks to the fetus and pregnant women, pregnant women were often excluded from clinical trials during the new drug approval phase. As a result, pregnant patients have been exposed to the high risk of taking drugs after the new drug is commercialized without specific safety information. This regulatory guidance reflects the current trend of regulatory agencies actively requiring the establishment of a data collection system to fill this information gap.

Three Key Methodologies for Effective Data Acquisition

The FDA proposes three key methodologies to secure reliable data. The first is the analysis of case reports and case series, which is useful for detecting rare cases. The second is the establishment of a prospective pregnancy registry, which registers patients before the pregnancy outcome is known and tracks them. Finally, to supplement the slow registration rate of the registry, it recommends linking real-world data (RWD), such as electronic health records (EHR) and healthcare claims data, in a complementary manner. Through a multidisciplinary approach, the accumulated high-quality data is expected to become a powerful tool for early screening of risk factors for drug use in pregnant women during the post-approval phase.

Changes in Regulatory Response by the Bio/Pharmaceutical Industry

Global pharmaceutical companies must design more sophisticated pregnancy safety assessment systems in the post-marketing surveillance (PMS) and clinical trial design phases after new drug approval. This may lead to an increase in research and development (R&D) budgets and operational burdens in the short term, but in the medium to long term, it will provide an opportunity to increase market competitiveness by clearly stating safety data in the product label. Unlike large pharmaceutical companies that have already established their own safety monitoring systems, small and medium-sized bio-venture companies with insufficient regulatory compliance capabilities may experience barriers to entry due to initial infrastructure investment costs. Companies should comprehensively review the process of collecting real-time data related to pregnancy from the planning stage.

Innovation in Maternal Healthcare and Clinical Decision-Making

The establishment of the new guidelines will provide scientific evidence-based safe prescription guidelines for pregnant patients and healthcare professionals who have not had alternative treatments. Healthcare professionals will be able to move away from passive prescriptions based on uncertainty by securing high-quality, real-time safety data, and will be able to design treatment paths optimized for both pregnant women and fetuses. Furthermore, it is expected to have a positive social impact by preventing secondary complications that may occur due to neglect of disease management during pregnancy, thereby raising the overall level of women's health and welfare.

Changes in Market Landscape and Future Growth Prospects

In the long term, this regulatory standardization is expected to be a catalyst for re-establishing the global harmonization of multinational clinical trial designs. Convergence research in various specialized fields such as pediatrics, obstetrics, genetics, and statistics will be activated, and the related digital healthcare and data analysis platform market will also have an opportunity to grow rapidly. In particular, specialized companies with cost-effective RWD analysis capabilities are likely to emerge as new players in the clinical research organization (CRO) market. Investors should consider the drug's expandability for prescription in pregnant women and post-market safety management capabilities as key indicators when evaluating the value of new drugs in the future.